- Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
- Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
- Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
Key statistics
On Thursday, Harmony Biosciences Holdings Inc (60H:BER) closed at 31.86, 0.00% below its 52-week high of 31.86, set on Sep 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | 31.90 |
Offer | 31.91 |
Previous close | 31.86 |
Average volume | -- |
---|---|
Shares outstanding | 56.79m |
Free float | 33.31m |
P/E (TTM) | 13.63 |
Market cap | 1.79bn USD |
EPS (TTM) | 2.32 USD |
Data delayed at least 15 minutes, as of Sep 28 2023 07:08 BST.
More ▼